Giá tốt.  trực tuyến

chi tiết sản phẩm

Created with Pixso. Nhà Created with Pixso. các sản phẩm Created with Pixso.
Thuốc ung thư phổi ngực
Created with Pixso. Jascayd Nerandomilast 18mg Tablets For Idiopathic Pulmonary Fibrosis And Progressive Pulmonary Fibrosis Intervention

Jascayd Nerandomilast 18mg Tablets For Idiopathic Pulmonary Fibrosis And Progressive Pulmonary Fibrosis Intervention

Tên thương hiệu: Boehringer Ingelheim
Số mô hình: Viên nén bao phim 18mg
MOQ: 1 chiếc
giá bán: Please contact a specialist WhatsApp:55342706
Thời gian giao hàng: Có thể thương lượng
Điều khoản thanh toán: Liên minh phương Tây, Moneygram, T/T.
Thông tin chi tiết
Nguồn gốc:
Hoa Kỳ
Chứng nhận:
FDA NDA 218764
Đặc điểm kỹ thuật:
18mg*60 viên/hộp
Chỉ định:
Xơ phổi vô căn, xơ phổi tiến triển
Mục tiêu:
PDE4B
Tên sản phẩm:
thuốc giảm đau Nerandomilast
Gợi ý:
Hãy làm theo lời khuyên của bác sĩ
Kho:
Bảo quản ở nhiệt độ 20°C đến 25°C, cho phép chênh lệch nhiệt độ môi trường trong khoảng từ 15°C đến
Nhiệt độ bảo quản:
20°C đến 25°C
Phạm vi nhiệt độ xung quanh:
15°C đến 30°C
Dạng bào chế:
Viên nén bao phim
Sức mạnh của máy tính bảng:
18mg
Kích thước gói:
60 viên/hộp
Enzim đích:
PDE4B
chi tiết đóng gói:
Có thể thương lượng
Khả năng cung cấp:
Có thể thương lượng
Làm nổi bật:

Jascayd Nerandomilast 18mg Idiopathic Pulmonary Fibrosis

,

Generic Nerandomilast 18mg Progressive Pulmonary Fibrosis

,

Jascayd BI 1015550 IPF PPF Tablets

Mô tả sản phẩm
Jascayd Nerandomilast for Idiopathic Pulmonary Fibrosis & Progressive Pulmonary Fibrosis Intervention
Product Overview

For professional medical use only under physician supervision

Manufacturer: Boehringer Ingelheim International GmbH

Generic Name: Nerandomilast

Brand Name: Jascayd

FDA Approval: NDA 218764

Indications

Jascayd is a highly selective PDE4B targeted inhibitor with anti-fibrotic and immunomodulatory effects. It is indicated for adult patients diagnosed with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). May be used alone or in combination with standard anti-fibrotic agents such as pirfenidone or nintedanib to reduce lung capacity decline and delay disease progression.

Dosage and Administration

Standard Maintenance Dose: 18 mg orally twice daily, 12 hours apart. Swallow whole with room temperature water, before or after meals. Do not split, chew, or crush tablets.

  • Mild/Moderate Hepatic Impairment (Child-Pugh A/B): No dose adjustment required
  • Severe Hepatic Impairment & End-Stage Renal Disease: Insufficient safety data - not recommended

Missed Dose: Take immediately if remembered on the same day. If less than 4 hours until next dose, skip the missed dose. Do not take double dose.

Specifications

Film-coated oral tablets: 18 mg per tablet, 60 tablets per box

Contraindications
  • Patients with severe hypersensitivity to nerandomilast or any excipient component
  • Pregnant and breastfeeding women without professional risk-benefit assessment
Warnings and Precautions
  • Gastrointestinal Effects: Mild diarrhea, nausea, and stomach discomfort common during early treatment. Persistent severe GI reactions require medical evaluation and dose adjustment
  • Liver Function Monitoring: Regular liver function tests recommended during long-term use to monitor transient transaminase elevations
  • Drug Interactions: Metabolized by hepatic oxidation. Professional dose assessment required when used with strong CYP3A modulators
  • Fertility Considerations: Effective contraception recommended for patients of reproductive potential throughout treatment
Common Adverse Reactions (≥5% incidence)

Diarrhea, nausea, headache, fatigue, decreased appetite. Transient liver enzyme abnormalities frequently observed in laboratory tests.

Storage Requirements

Store at 20°C-25°C. Temporary exposure to 15°C-30°C acceptable. Protect from light. Keep in original packaging until use.